Target intelligence / Profile preview

Homeobox protein Hox-B7 (HOXB7)

Target
HOXB7
Molecular classification
Transcription factor, Homeobox protein, DNA-binding protein
01

Overview

Homeobox protein Hox-B7 (HOXB7) is a sequence-specific transcription factor belonging to the Antennapedia (Antp) homeobox family. It contains a conserved homeobox DNA-binding domain and plays a crucial role in the regulation of embryonic development by providing cells with positional identity along the anterior-posterior axis. HOXB7 is also involved in adult tissue processes, especially cell proliferation and differentiation. Overexpression or aberrant expression of HOXB7 is associated with tumor growth, progression, and metastasis in a variety of cancers, where it can influence pathways such as EGFR, FGF2, and TGFβ signaling, and is recognized as a marker of poor prognosis in certain cancer subtypes. The biological effects of HOXB7 may vary between cellular contexts and tumor types, sometimes promoting or counteracting aggressive phenotypes depending on the molecular background[1][2][3][4][5][7].

Other names
HOX2CHHO.C1HOX2Hox-2.3homeobox protein Hox-2Chomeo box 2Chomeo box B7homeo box c1 proteinHox-B7
02

Mechanism of action

For drug development, proposed mechanisms include inhibition of HOXB7 expression (e.g., using siRNA or antisense oligonucleotides), disruption of HOXB7 interactions with co-factors like PBX1 or CREB-binding protein, or indirect targeting via downstream signaling pathways such as EGFR or TGFβ signaling[2][4].

03

Biological functions

Cell proliferationCell differentiationEmbryonic development (specifies positional identity along the anterior-posterior axis)Regulation of gene expressionEpithelial-mesenchymal transition (EMT)DNA repairAngiogenesisApoptosis
04

Disease associations

Cancer (notably breast cancer, glioma, melanoma, ovarian carcinoma, and others)Barrett esophagusBilateral renal aplasiaOther malignancies (evidence for roles in liver, pancreas, and other solid tumors)
05

Safety considerations

As a transcription factor, HOXB7 is not traditionally "druggable," so direct inhibitors may have off-target or developmental toxicityTargeting broad developmental regulators risks unintended effects on normal tissue homeostasis and stem cell compartments
06

Interacting drugs

EGFR inhibitors (via HOXB7 upregulation of EGFR)

1 more in the full profile.

07

Biomarkers

HOXB7 expression as a prognostic biomarker for poor outcome in several cancers, including breast cancer and gliomaHigh HOXB7 correlates with greater grade and aggressiveness, especially in triple-negative breast cancer (TNBC)High HOXB7 correlates with greater grade and aggressiveness in IDH1 wild-type gliomas

Beyond the preview

Go deeper on Homeobox protein Hox-B7 (HOXB7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homeobox protein Hox-B7 (HOXB7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call